Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
MACS2226
1 other identifier
expanded_access
N/A
1 country
3
Brief Summary
Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 4, 2012
CompletedFirst Posted
Study publicly available on registry
June 6, 2012
CompletedApril 24, 2015
April 1, 2015
June 4, 2012
April 23, 2015
Conditions
Keywords
Interventions
800 mg per day
Eligibility Criteria
You may qualify if:
- Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained.
You may not qualify if:
- N/A.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
Novartis Investigative Site
Guangzhou, 510080, China
Novartis Investigative Site
Shanghai, 200025, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jie Zhong, M.D.
Ruijin Hospital of Shanghai Jiaotong University
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 4, 2012
First Posted
June 6, 2012
Last Updated
April 24, 2015
Record last verified: 2015-04